Most Read

This marks the first NMPA-approved monoclonal antibody that targets gastric tumour cells expressing the biomarker CLDN18.2. The approval offers a new, highly targeted treatment option for individuals particularly

This decision follows the positive outcomes from the multicentre, open-label Phase II TRUST-I trial. The single-arm trial was instrumental in assessing the therapy’s tolerability, efficiency, and safety in

This strategic move involves a total payment of $18m and terminates prior agreements with VBI, including future milestone and royalty obligations. Under the terms of the agreement, Brii

As per the deal, WuXi Bio will offer comprehensive discovery services, including antibody generation, spearhead detection, optimisation, and developability assessment. These services will be supported by WuXi’s single

The new indication specifically targets unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) expressing programmed death-ligand 1 (PD-L1). The approval for the

This collaboration aims to leverage Axcelead’s DegLead Platform, an integrated service solution designed for the next generation of small-molecule drug discovery, to support Astellas’ discovery efforts and contribute

A human monoclonal antibody, BAT2206 is currently undergoing regulatory review with several health authorities, including the China National Medical Products Administration (NMPA), the US Food and Drug Administration

BAL2420 is a lipooligosaccharide phosphoethanolamine transferase A (LptA) inhibitor, a new class of antibiotics with bactericidal activity against Gram-negative bacteria, including drug-resistant strains. The additional CARB-X funding is

The collaboration focuses on a three-asset portfolio of preclinical next-wave ADCs. These ADC assets were developed through a joint effort between WuXi Biologics and Hangzhou DAC Biotechnology, leveraging